Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
54,400
+200 (0.37%)
At close: Feb 27, 2026
75.48%
Market Cap 786.56B
Revenue (ttm) n/a
Net Income (ttm) -39.26B
Shares Out 14.46M
EPS (ttm) -2,755.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,382
Average Volume 117,714
Open 54,800
Previous Close 54,200
Day's Range 53,700 - 55,400
52-Week Range 23,750 - 58,100
Beta 1.40
RSI 59.61
Earnings Date Mar 13, 2026

About Curocell

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.